PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2019 Financial Results
SOUTH PLAINFIELD, N.J., Oct. 15, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2019 financial results and provide an update on the company's business and outlook on Tuesday, October 29, 2019 at 4:30 p.m. (ET) after closing of the market.
The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 9224968. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.
About PTC Therapeutics, Inc. PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
NanoString Technologies, Inc. ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that substantially all of its assets will be acquired by Bruker Corporation ("Bruker"),...
Benchmark Senior Living, the largest senior housing provider in New England, today announced that 44 of its Northeast continuing care, independent living, assisted living and Mind & Memory Care communities have been named U.S. News & World Report...
Pieper Veterinary, a Northeastern-based family of primary, specialty, and emergency care veterinary hospitals, is excited to announce they have partnered with Lebanon Veterinary Hospital in Lebanon CT. This partnership continues Pieper's strategy to...
NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of...
Acadia Pharmaceuticals Inc. today announced that two oral presentations featuring DAYBUEtm (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO....
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica's relaunch of its pivotal...